Bertamini, L., Terragna, C., Bolli, N., Moreau, P., Rodriguez-Otero, P., Boccadoro, M., Bladé, J., Donk, N. W. V. D., Gay, F., Mina, R., Perrot, A., Ho, P. J., Broijl, A., Beksac, M., Duin, M. V., Vieyra, D., Borgsten, F., Rowe, M., Dimopoulos, M. A., Sonneveld, P. (2026). New IMS/IMWG risk criteria by next-generation sequencing (NGS): Analysis of daratumumab benefit in both high- and standard-risk patients (pts) in the PERSEUS study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.7505